Company / Revenue
Caribou Biosciences, Inc. Revenue History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue
$11.2M
FY2025
5-year range
$5.8M / $34.5M
FY2021-FY2025
Trend
-67.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $14M to $11M over the past 2 years.
Based on SEC 10-K filings.
$11M in FY2025 with a 3-year CAGR of +5.2%.
Declined from $14M to $11M over the past 2 years.
Revenue over time
Growth rates
- 3-Year CAGR
- +5.2%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of +5.2%, indicating consistent growth.
- In FY2025, revenue decreased 67.6% year-over-year.
- Peak revenue was recorded in FY2024.
- Lowest revenue in the period was in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.99 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $11.2M | -67.6% |
| FY2024 | $34.5M | +148.9% |
| FY2023 | $13.9M | +44.3% |
| FY2022 | $9.6M | +65.8% |
| FY2021 | $5.8M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026